Øivind Torkildsen is professor of neurology, Head of Section for Neurology at the University of Bergen, Norway and consultant neurologist at the Department of Neurology, Haukeland Univiersity Hospital, Norway. He has a long research experience in both clinical and preclinical studies.  He is the principal investigator and national coordinator of both industry- and investigator initiated studies, and he has since 2004 conducted a number of clinical trials in multiple sclerosis.  

His current research focuses on the etiology of the disease and on discovering new therapeutic options against multiple sclerosis. 

He is a member of the Norwegian Medical Association, the Norwegian Neurological Association and Fellow of European Academy of Neurology (FEAN). He is coordinating the EBV-MS project financed by the Horizon 2023 EU grant (Overview of all EBV-MS project partners | EBV-MS | UiB).

Horizon - EBV-MS  - https://www.uib.no/en/ebvms/170748/overview-all-ebv-ms-project-partners

RAM-MS - http://ram-ms.no

OVERLORD-MS - https://www.helse-bergen.no/kliniske-studier/okrelizumab-versus-rituksimab-som-behandling-for-tidlig-attakvis-multippel-sklerose-overlord-ms